Given the focus on CD34-expressing leukemia, the results may not be generalizable to other immunophenotypes of AML, and the sample numbers may have limited our ability to identify and verify some prognostic transcripts – especially those with modest clinical effect sizes. This evidence concerns the gene CD34 and acute myeloid leukemia.